Nexstim enrols last patient in supplementary Phase III E-FIT trial
Helsinki, Finland: 6 January 2018 - Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, announces that it has successfully completed enrolment in its supplementary Phase III clinical trial, known as E-FIT (ELECTRIC FIELD NAVIGATED 1HZ RTMS FOR POST-STROKE MOTOR RECOVERY TRIAL), evaluating the use of Nexstim's NBT® system in upper extremity motor rehabilitation following stroke.
The supplemental trial is being conducted at five leading clinical centres in the US and has recruited its planned total of 60 patients. The E-FIT trial uses a new sham comparator and has been designed to provide data to supplement the completed Phase III NICHE trial, which demonstrated excellent results in the active group, with 2/3 patients showing a clinically meaningful response. Active group data from the Phase III NICHE trial will be pooled with data from the E-FIT trial in the planned filing with the FDA.
More info on Nexstim's website
Next > DMC Biotechnologies announces first close of $1.75M equity financing led by Capricorn Venture Partners
Previous > Agendia and Bluebee Partner to Bring New NGS-Based MammaPrint®BluePrint® Breast Cancer Kit to Market